<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195871</url>
  </required_header>
  <id_info>
    <org_study_id>LL03</org_study_id>
    <nct_id>NCT00195871</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma</brief_title>
  <official_title>A Multicenter, Phase 2 Study, to Evaluate Safety and Efficacy of an Acute Lymphoblastic Leukemia (ALL) Intensive Chemotherapy for Adult Lymphoblastic Lymphoma (LL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and the efficacy of an adult
      &quot;acute lymphoblastic leukaemia&quot; type chemotherapy in patients less than 60 years with
      lymphoblastic lymphoma. Treatment principle is based on an intensive induction and a delayed
      intensification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoblastic lymphomas (LL) are rare and represent less than 2% of the malignant non-Hodgkin
      lymphomas (NHL). The distinction between a LL and an acute lymphoblastic leukaemia (ALL) is
      difficult; it is arbitrarily based on the percentage of medullary blasts. Above 20% of
      blasts, it is an ALL. In both cases, the same type of cells is affected: the lymphoblast.
      Thus the LL were treated either as aggressive NHL or as ALL. The results of the various
      clinical studies, have shown a best efficacy of ALL type treatments(in terms of overall
      survival and disease free survival). These treatments are based on an induction phase with
      reinforced cyclophosphamide and L-asparaginase, and a re-use of the first drugs after
      consolidation (delayed intensification). The prognostic factors of ALL are now better
      defined, determining risk groups. According to these prognostic indicators, the allograft
      could be proposed in first complete remission. Indicators are biological (hyperleukocytosis,
      chromosomal abnormalities as t(4;11), t(9;22), t(1;19) translocations), clinical (central
      nervous system involvement), evolutive (salvage therapy needed to obtain complete remission),
      consideration of early response (cortico-sensibility and chemo-sensibility) and molecular
      responses (residual disease). On the other hand, the prognostic factors of LL are not well
      known. This study should permit to better define them. So the prognostic indicators of ALL,
      in this study, will be decisional for the indication of allograft. This treatment is based on
      a parallel currently recruiting adult patients with ALL (protocol GRAALL 2003).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2004</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 y</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival ; Complete response rate ; Overall Survival ; Progression rate; Relapse rate ; Central Nervous System or meningeal relapse rate ; medullary relapse rate ; toxicities.</measure>
    <time_frame>2 y</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">155</enrollment>
  <condition>Lymphoblastic Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide</intervention_name>
    <description>coventional dosages</description>
    <other_name>nono</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hematopoietic stem cell allograft</intervention_name>
    <description>conventional procedures</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with lymphoblastic lymphoma.

          -  Aged from 18 to 59 years.

          -  Medullary blasts rate less than 20%

          -  Non previously treated

          -  With or without central nervous system or meningeal involvement.

          -  No contra-indication to anthracyclines.

          -  No contra-indication to intensive treatments

          -  Negative HIV serology test

          -  Negative pregnancy test for all female patients of childbearing potential.

          -  Able to be regularly followed up.

        Exclusion Criteria:

          -  Evolutive cancer with the exception of non melanoma skin tumours or stage 0 (in situ)
             cervical carcinoma.

          -  Prior treatment with chemotherapy.

          -  Lymphoblastic Transformation of chronic myeloid leukaemia

          -  Patient unable to be regularly followed-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Lepretre, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Henri Becquerel, Rouen, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Dombret, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Ifrah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire d’Angers, FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chr de La Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires U C L de Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C H U D'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Region Annecienne</name>
      <address>
        <city>Annecy</city>
        <zip>74011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lens</name>
      <address>
        <city>Lens</city>
        <zip>62300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Benite Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseilles</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitie Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marechal Joffre Hospital</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Reims Robert Debre Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de La Loire</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bretonneau Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In French)</description>
  </link>
  <reference>
    <citation>Le Gouill S, Lepretre S, Brière J, Morel P, Bouabdallah R, Raffoux E, Sebban C, Lepage E, Brice P. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia. 2003 Nov;17(11):2220-4.</citation>
    <PMID>14576732</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 6, 2013</last_update_submitted>
  <last_update_submitted_qc>November 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Henri Becquerel</investigator_affiliation>
    <investigator_full_name>Stephane Lepretre</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Non-Hodgkin</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoblastic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 31, 2016</submitted>
    <returned>October 21, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

